Alpha Teknova (NASDAQ:TKNO) Releases Earnings Results, Beats Expectations By $0.02 EPS

Alpha Teknova (NASDAQ:TKNO) issued its quarterly earnings results on Wednesday. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02, FiscalAI reports. The business had revenue of $12.19 million for the quarter, compared to analysts’ expectations of $10.95 million. Alpha Teknova had a negative net margin of 38.37% and a negative return on equity of 24.38%.

Here are the key takeaways from Alpha Teknova’s conference call:

• Second-quarter revenue rose 18% to a record $12 million, with growth broad-based across customers and major markets aside from cell and gene therapy. Gross margin improved to 40.1%, while free cash outflow declined sharply to $0.6 million from $2.3 million a year earlier.
• Teknova raised 2026 revenue guidance to $45 million-$47 million, implying approximately 14% growth at the midpoint, and now expects full-year free cash outflow below $8 million.
• Management cited potential longer-term growth from more than 70 therapies and diagnostics in clinical trials, improving biotech funding, and commercial investments, but said the funding benefit has not yet reached revenue and expects most sales impact from the commercial buildout in early 2027.
• Cell and gene therapy demand remains muted, while operating expenses are expected to remain at least $8 million per quarter through year-end. The company still expects adjusted EBITDA to turn positive only after reaching approximately $52 million-$57 million in annualized revenue, and its 2027 target remains in the low-$50-million range.
• The company officially launched Build-Tek, an AI-powered custom-product configurator intended to shorten custom order design from weeks to a few business days and encourage catalog customers to adopt higher-value custom products; management expects it to support growth rather than generate direct software fees.

Alpha Teknova Stock Performance

NASDAQ:TKNO traded down $0.12 during mid-day trading on Friday, hitting $6.42. The stock had a trading volume of 48,899 shares, compared to its average volume of 185,629. The stock has a market capitalization of $343.91 million, a price-to-earnings ratio of -20.69 and a beta of 0.64. The company has a 50 day simple moving average of $5.21 and a 200-day simple moving average of $3.73. Alpha Teknova has a 52 week low of $1.91 and a 52 week high of $6.68. The company has a current ratio of 4.59, a quick ratio of 3.60 and a debt-to-equity ratio of 0.20.

Institutional Investors Weigh In On Alpha Teknova

Several large investors have recently made changes to their positions in TKNO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Alpha Teknova during the second quarter worth approximately $29,000. JPMorgan Chase & Co. increased its position in Alpha Teknova by 123.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 8,163 shares of the company’s stock valued at $40,000 after acquiring an additional 4,504 shares during the period. Larson Financial Group LLC increased its position in Alpha Teknova by 58.5% in the 3rd quarter. Larson Financial Group LLC now owns 9,387 shares of the company’s stock valued at $58,000 after acquiring an additional 3,464 shares during the period. Sherbrooke Park Advisers LLC acquired a new stake in Alpha Teknova in the 3rd quarter valued at approximately $94,000. Finally, Susquehanna International Group LLP raised its stake in Alpha Teknova by 25.0% during the 3rd quarter. Susquehanna International Group LLP now owns 16,206 shares of the company’s stock valued at $100,000 after acquiring an additional 3,246 shares in the last quarter. Institutional investors and hedge funds own 13.81% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on TKNO shares. Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Teknova in a research note on Friday, July 17th. Roth Capital initiated coverage on shares of Alpha Teknova in a report on Wednesday. They issued a “buy” rating and a $7.00 price objective for the company. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $7.00.

About Alpha Teknova

Alpha Teknova, Inc (NASDAQ: TKNO) is a life science tools and reagents company that develops, manufactures and distributes proprietary products to support research, drug discovery and biomanufacturing. Its offerings target academic institutions, pharmaceutical and biotechnology firms, and diagnostic developers, with a focus on high-purity reagents and optimized workflows designed to accelerate molecular biology and protein science applications.

The company’s portfolio includes molecular biology reagents, cell culture buffers, in vitro translation kits, custom recombinant proteins, high-throughput screening buffers and other specialized formulations.